17.29
-0.4(-2.26%)
Currency In USD
| Previous Close | 17.69 |
| Open | 17.7 |
| Day High | 17.71 |
| Day Low | 16.92 |
| 52-Week High | 18.15 |
| 52-Week Low | 8.03 |
| Volume | 1.4M |
| Average Volume | 1.75M |
| Market Cap | 2.07B |
| PE | -23.68 |
| EPS | -0.73 |
| Moving Average 50 Days | 15.43 |
| Moving Average 200 Days | 14.27 |
| Change | -0.4 |
If you invested $1000 in Arcutis Biotherapeutics, Inc. (ARQT) since IPO date, it would be worth $793.12 as of September 13, 2025 at a share price of $17.29. Whereas If you bought $1000 worth of Arcutis Biotherapeutics, Inc. (ARQT) shares 3 years ago, it would be worth $845.89 as of September 13, 2025 at a share price of $17.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
GlobeNewswire Inc.
Sep 03, 2025 3:43 PM GMT
If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to topical steroids and vitamin-D analogsZORYVE cream is
Arcutis to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 19, 2025 8:00 PM GMT
WESTLAKE VILLAGE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
GlobeNewswire Inc.
Jul 23, 2025 8:00 PM GMT
WESTLAKE VILLAGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will